Browse > Article

Rare Disease Research and Orphan Drug Development  

Lee, Shinhaeng (Yonsei Institute of Pharmaceutical Sciences, Yonsei University)
Lee, Jangik I. (Yonsei Institute of Pharmaceutical Sciences, Yonsei University)
Publication Information
Korean Journal of Clinical Pharmacy / v.23, no.1, 2013 , pp. 1-13 More about this Journal
Keywords
rare disease; orphan drug; orphan designation; orphan drug act; academic institution;
Citations & Related Records
연도 인용수 순위
  • Reference
1 University of Minnesota. Center for Orphan Drug Research. Available at http://www.health.umn.edu/education/Orphan Drugs/index.htm (Last accessed December 30, 2012)
2 Keck Graduate Institute. Center for Rare Disease Therapies. Available at http://www.kgi.edu/faculty-and-research/kgicenters/ center-for-rare-disease-therapies.html (Last accessed December 30, 2012)
3 Villa S CA, Reich MR. Orphan drug legislation: Lessons for neglected tropical diseases. Int J Health Plann Manage 2009; 24: 27-42.   DOI
4 Public Law 97-414. Orphan Drug Act. 97th Congress. 1982. Congressional Record, Vol. 128.
5 The European Parliament and the Council of the European Union. Orphan Drug Products. 1999. Regulation (EC) No. 141/2000.
6 Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: Development trends and strategies. J Pharm Bioallied Sci 2010; 2: 290-9.   DOI
7 Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis 2008; 3: 33.   DOI
8 Rare Disease Legislative Advocates. President Signs Rare Disease Legislation into Law. July 9, 2012. Available at http://rareadvocates.org/president-signs-new-legislation/ (Last accessed December 30, 2012)
9 Global Genes. FDA User Fee Bill Is Landmark Legislation - Major Wins for the Rare Disease Patient Community Led by RDLA. June 28, 2012. Available at http://globalgenes.org/ fda-user-fee-bill-is-landmark-legislation-grassroots-efforts-byrare- disease-patients/ (Last accessed February 20, 2013)
10 Korean Food and Drug Administration. Regulation on Orphan Drug Designation. 1998. Notification No. 1998-23.
11 Japanese Ministry of Health. Labour and Welfare, Orphan Drug Amendment to Pharmaceutical Affairs Law. 1993.
12 Hudson I, Breckenridge A. The challenges of orphan drugs and orphan diseases: real and imagined. Clin Pharmacol Ther 2012; 92: 151-3.   DOI
13 Office of Inspector General. United States Department of Health and Human Services. The Orphan Drug Act implementation and impact. 2001.
14 Korean Food and Drug Administration. Regulation on Orphan Drug Designation. 2010. Notification No. 2010-17.
15 United States Food and Drug Administration. The Orphan Drug Regulations. 1992. Final Rule, 57 FR 62076 21 CFR Part 316.
16 Lev D, Thorat C, Phillips I, Thomas M, Imoisili MA. The routes to orphan drug designation--our recent experience at the FDA. Drug Discov Today 2012; 17: 97-9.   DOI
17 Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy (New York) 2010; 95: 216-28.   DOI
18 Rao GR. FDA Orphan Drug Designation 101. October 1, 2012. Available at http://www.fda.gov/downloads/ForIndustry/ Developing Products for Rare Diseases Conditions/OOPD NewsArchive/UCM324031.ppt (Last accessed February 20, 2013)
19 Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009; 523-31.
20 Sadler J, Blinder M. Von Willebrand disease: diagnosis, classification, and treatment. In Colman R, Marder V, Clowes A, George J, Goldhaber S eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: p. 905-21.
21 IMS Institute for Healthcare Informatics. The Global Use of Medicines: Outlook Through 2016. July 2012. Available at http://www.imshealth.com/deployedfiles/ims/ Global/Content/Insights/IMS%20Institute%20for% 20Healthcare%20Informatics/Global%20Use%20of% 20Meds%202011/Medicines_Outlook_Through_2016_ Report.pdf (Last accessed December 30, 2012)
22 Kim CR. 바이오의약품 분야 희귀의약품 관리 정책 방향. 제 3차 연세대학교 의료원 희귀질환 치료제 개발 세미나. August 20, 2012.
23 United States Food and Drug Administration. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. March 2, 2011. Available at http://www. fda.gov/AdvisoryCommittees/Committees Meeting Materials/ Drugs/Advisory Committeefor Pharmaceutical Scienceand Clinical Pharmacology/ucm240583.htm (Last accessed December 30, 2012)
24 Light R, Singer J, Willett J. By Design: Planning research on higher education: Harvard University Press; 1990.
25 Coles LD, Cloyd JC. The role of academic institutions in the development of drugs for rare and neglected diseases. Clin Pharmacol Ther 2012; 92: 193-202.   DOI
26 Burrill S. Life Sciences: Looking Back to See Ahead. San Francisco, CA: Burrill & Company; 2011.
27 Braun MM, Farag-El-Massah S, Xu K, Cote TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010; 9: 519-22.
28 Kriel RL, Cloyd JC, Hadsall RS, Carlson AM, Floren KL, Jones-Saete CM. Home use of rectal diazepam for cluster and prolonged seizures: Efficacy, adverse reactions, quality of life, and cost analysis. Pediatr Neurol 1991; 7: 13-7.   DOI
29 Pittman SB. Orphan Drug Approvals Dramatically Up Relaive to Non-Orphan Indications in 2011. Feb 1, 2012. Available at http://www.fdalawyersblog.com/2012/02/orphandrug- approvals-dramatic.html (Last accessed December 30, 2012)
30 Ariyanchiara S. Global Markets for Orphan Drugs. May 2010. Available at http://www.bccresearch.com/report/orphan-drugsmarket- phm038c.html (Last accessed December 30, 2012)
31 Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG. Drug repositioning for orphan diseases. Brief Bioinform 2011; 12: 346-56.   DOI
32 Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, Jarvik JW, Gresham HD, Haynes MK, Hjelle B, Hromas R, Hudson L, Mackenzie DA, Muller CY, Reed JC, Simons PC, Smagley Y, Strouse J, Surviladze Z, Thompson T, Ursu O, Waller A, Wandinger-Ness A, Winter SS, Wu Y, Young SM, Larson RS, Willman C, Sklar LA. Drug Repurposing from an Academic Perspective. Drug Discov Today Ther Strateg 2011; 8: 61-9.   DOI
33 Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011; 57: 153-60.   DOI
34 The University of Notre Dame. The Center for Rare and Neglected Diseases. Available at http://www.nd.edu/-crnd/ index.html (Last accessed December 30, 2012)
35 Boston Children's Hospital. Manton Center for Orphan Disease Research. Available at http://www.health.umn.edu/ education/OrphanDrugs/index.htm (Last accessed December 30, 2012)
36 About PR Newswire. PROLOR Biotech's Longer-acting Human Growth Hormone Receives Orphan Drug Designation in Europe. February 13, 2013. Available at http://www. prnewswire.com/news-releases/prolor-biotechs-longer-actinghuman- growth-hormone-receives-orphan-drug-designation-ineurope- 190994291.html (Last accessed February 20, 2013)
37 Lewis D. Regulatory Aspects of Orphan Drugs - FDA Perspective. 7th Annual International Conference for Rare Diseases and Orphan Drugs. February 4, 2012. Available at http://icord.se/wp-content/uploads/Session-3-Debra-Lewis.pdf (Last accessed December 30, 2012)
38 Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther 2007; 6: 1175-9.   DOI
39 Kim CR. New Regulatory Policy Adapted for Biological Product Area. Proceedings of 2012 Annual Meeting of KFDC. October 12, 2012.
40 United States Food and Drug Administration. FDA/CDER Small Business Chronicles - Orphan Drugs. July 13,2012.Camargo Pharmaceutical Services. Publications by Experts at Camargo Pharmaceutical Services 2006 through 2012. Available at http://www.fda.gov/downloads/Drugs/Development Approval Process/SmallBusinessAssistance/UCM 311928.pdf (Last accessed December 30, 2012)
41 Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today 2012; 17: 660-4.   DOI
42 United States Food and Drug Administration. FY 2011 Innovative Drug Approvals. November 2011. Available at http://www.fda.gov/AboutFDA/ReportsManualsForms/ Reports/ucm330502.htm (Last accessed December 30, 2012)
43 Thomson Reuters. Orphan Drugs Show Blockbuster Potential. August 23, 2012. Available at http://blog. thomsonreuters.com/index.php/orphan-drugs-show-block buster-potential/ (Last accessed December 30, 2012)